1.

Lacroix, A., Bolt, E., Tremblay, J., Dupr, J., Poitras, P., Fournier, H., Garon, J., Garrel, D., Bayard,
F., Taillefer, R., Flanagan, R., and Hamet, P. Gastric inhibitory polypeptide-dependent cortisol
hypersecretion - a new cause of Cushing's syndrome. N. Engl. J. Med.; 327:974-980. 1992
(274citations) IF 47.05

2.

Gagner, M., Lacroix, A., and Bolt, E. Laparoscopic approach to adrenalectomy in Cushing's
syndrome and pheochromocytoma. Letter to the Editor. N. Engl. J. Med.; 327:1033. 1992 (1361
citations) IF 47.05

3.

Lacroix, A., NDiaye, N., Tremblay, J., and Hamet, P. Ectopic and abnormal hormone receptors in
adrenal Cushings syndrome. Endocrine Reviews, 22 :75-110, 2001 (278 citations). IF 19.76

4.

Lacroix, A., Tremblay, J., Rousseau, G., Bouvier, M., and Hamet, P. Propranolol therapy for ectopic
-adrenergic receptors in adrenal Cushings syndrome. New Engl. J. Med.; 337:1429-1434. 1997
(178 citations) IF 47.05

5.

Lacroix, A., Hamet, P., Boutin, JM. Leuprolide acetate therapy in Luteinizing Hormone-dependent
Cushings syndrome. New England Journal of Medicine. 341:1577-81. 1999 (169 citations). IF
47.05

6.

Arnaldi, G., Angeli, A., Atkinson, A.B., Bertagna, X., Cavagnini, F., Chrousos, G., Fava, G.A.,
Findling, J., Gaillard, R.C., Grossman, A.B., Kola, B., Lacroix, A., Mancini, T., Mantero F., NewellPrice, J., Nieman, L.K., Sonino, N., Vance M.L., Giustina A., Boscaro M. Diagnosis and
complications of Cushings syndrome : A consensus statement. J. Clin. Endocrinol. Metab.,
88(12):5593-602, 2003. (927 citations) IF 6.20

7.

Biller B.M.K., Grossman A.B., Stewart P.M., Melmed S., Bertagna X., Bertherat J., Buchfelder M.,
Colao A., Hermus A.R., Hofland L.J., Klibanski A., Lacroix A., Lindsay J.R., Newell-Price J.,
Nieman L.K., Petersenn S., Sonino N., Stalla G.K., Swearingen B., Vance M.L., Wass J.A.H. and
Boscaro M. Treatment of ACTH-dependent Cushings Syndrome: A Consensus Statement. J. Clin.
Endocrinol. Metab. 93: 2454-62, 2008 (452 citations)

8.

Lacroix A, Baldacchino V, Bourdeau I, Hamet P and Tremblay P. Cushing's syndrome variants

secondary to aberrant hormone receptors. Trends in Endocrinology and Metabolism 15: 375-382,
2004. (79 citations) IF 8.48

9.

Lampron A, Bourdeau I, Oble S, Godbout A, Schurch W, Arjane P, Hamet P, and Lacroix A.

Regulation of aldosterone secretion by several aberrant receptors including for GIP in a patient with
an aldosteronoma. J Clin Endocrinol Metab. 94:750-6, 2009. (27 citations) IF 6.20

10.

Hsiao H-P, Verma S, Nandagopal R, Boikos SA, Bourdeau I, Keil MF, Robinson-White AJ,
Kirschner LS, Lacroix A, and Stratakis CA. A Molecular and Clinical Genetic Investigation of
ACTH-Independent Macronodular Adrenal Hyperplasia Compared to Other, Common Adrenocortical
Tumors: Evidence for Heterogeneity, Overlap with Other Tumor Syndromes and Frequent But
Atypical Hormonal Secretion. J Clin Endo Metab 94: 2930-37, 2009. (53 citations) IF 6.20

11.

Lacroix A. Approach to the patient with adrenal carcinoma. J Clin Endocrinol Metab. 95:4812-22,
2010. (52 citations) IF 6.20

12.

Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J, Hamet P. Aberrant G-protein coupled
receptor expression in relation to adrenocortical overfunction. Clin Endocrinol (Oxf).73:1-15, 2010
(47 citations) IF 3.32

13.

Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline

monotherapy in the long-term treatment of Cushings disease. Eur J Endocrinol. 163: 1-9, 2010 (83
citations) IF 3.48

14.

Colao AM, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D,

Salgado LR, and Biller BMK, on behalf of the Pasireotide B2305 Study Group (Lacroix A). A 12Month Phase 3 Study of Pasireotide in Cushings Disease. N Engl J Med 366 : 914-24, 2012. IF
47.05

15.

Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C,

Lacroix A Jarzab B, Sorbye H, Torpy D, Stepan V, Arlt W, Schteingart D, Kroiss M, Leboulleux S,
Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la
Fouchardire C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink
H, Sender M, Edgerly M, Kenn W, Fojo T, Mueller HH, Skogseid B, for the FIRM-ACT study
group. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med
366(23):2189-97, 2012 May 2. (155 citations) IF 47.05

16.

Lacroix A. Heredity and cortisol regulation in bilateral macronodular adrenal hyperplaisia. Editorial N
Engl J Med. 369 Nov 28:2147-2149, 2013(8 citations) IF 47.05

17.

Pivonello, R., Petersenn, S., Newell-Price, J., Findling, J.W., Gu, F., Maldonado, M.,
Schoenherr, U., Sen, K., Salgado, L.R., Lacroix, A., Schopohl, J. and Biller, B.M.K.
on behalf of the Pasireotide B2305 Study Group. Significant improvement in clinical signs
and symptoms of Cushings disease during 12 months of pasireotide therapy: results from a
randomized, double-blind, Phase III study. Clin. Endocrinol. (Oxf) 81: 408-417, 2014

18.

Alencar, G.A., Lerario, A.M., Nishi, M.Y., Mariani, B.M.M., Almeida, M.Q., Tremblay, J.,
Hamet, P., Bourdeau, I., Zerbini, M.C.N., Pereira, M.A.A., Gomes, G.C., Rocha, M.D.S.,
Chambo, J.L., Lacroix, A., Mendonca, B.B., Fragoso, M.C.B.V. ARMC5 Mutations are a
frequent cause of primary macronodular adrenal hyperplasia. J. Clin. Endocrinol. Metab. 99:
E1501-1509, 2014. (12 citations) IF : 6.20

19.

Van Uum, S., Hurry, M., Petrella, R., Koch, C., Dranitsaris, G., Lacroix, A. Management of
patients with Cushings disease: A Canadian cost of illness analysis. J. Popul. Ther. Clin.
Pharmacol. 21: e508-e517, 2014.

20.

Lacroix A, Felders RA, Stratakis CA, Nieman L. Cushings syndrome. Invited Seminars in Lancet
Sous presse 2015